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     What is the most exciting aspect of your current research?  
 
The advent of high-throughput molecular analysis means that we can now look globally at the 
exquisitely intertwined genomic, transcriptomic, proteomic and metabolic networks that govern 
the complex adaptive systems called cells. Most efforts so far concentrate on defining the 
identities and amounts of the players, be it genes, proteins, RNA or metabolites. A different, 
crucial aspect that has been somewhat neglected is that cells are inhomogeneous with 
specialized organelles in different spatial locations that carry out many specific functions. This 
requires sophisticated cross-organelle communication between different subcellular spaces. We 
now have extensive data about the dynamic subcellular redistribution of multiple proteins 
involved in processes like DNA replication or response to oxidative stress. Focussing on the 
requirement for efficient subcellular spatial communication is giving new pictures of cellular 
functional organization and its connection to disease. For example, we have initial results 
suggesting that perturbation of cellular spatial control is a major contributor to dysfunction of 
breast cancer cells. 
      How might your recent work impact on clinical disease treatment/management? 
 New concepts about cellular function will lead to new approaches to development of treatments. 
If the major response of breast cancer cells to estrogen exposure is not changes in gene 
expression, but rather massive changes in subcellular spatial organization of proteins, we 
should be thinking about the dominant cellular response when trying to design pharmaceuticals 
for treatment. 
      What changes would you like to see made to address challenges associated with big data 
in your field? 
 At present there seems to be a schism between big data and other forms of research. For 
example, there are enormous numbers of large scale measurements of gene expression. In 
terms of analysing the fundamental organization of cells we think these kinds of measurements 
have reached a plateau in their usefulness and that even more measurements will not help 
much. This can, for example, be seen in attempts to correlate genetic variability with complex 
diseases. We already have lots of examples of genes that are associated with a disease, but 
are neither necessary nor sufficient for the disease. This seems to be related to population 
differences, e.g. that a gene/protein is only “defective” in the context of the genome/proteome of 
an individual. This is leading to the concept that functional networks involving concerted action 
of many genes, proteins, metabolites, etc. need to be identified by combining many kinds of 
input information with clinical information. This gets us back again to incomplete understanding 
of basic aspects of cellular function – we can detect hundreds, even thousands of genes that 
correlate with some disease, but we very often don’t have much idea of why this is so.  
 In some ways the most useful and reliable information about individual genes/proteins is still 
coming from more conventional, low-throughput approaches that incrementally analyse many 
functional aspects of the same gene/protein. For example, de novo prediction of gene/protein 
function from massive amounts of high throughput data has not been very successful and 
conventional low-throughput experiments regularly identify new, “unexpected” functions of 
proteins. We think that one reason for this relates to spatial organization of cells. Many proteins 
have multiple functions in different subcellular locations and a defining characteristic is the 
dynamic redistribution of proteins between different functions/locations in response to cellular 
environment. This often occurs with no change at all in the expression/abundance of the 
protein. 
 A schism arises because the high-throughput data is often filed away in databases and the 
computational, predictive efforts based on such data are often in terms of “global” parameters 
and are not analysed and presented in forms that “wet biologists” find useful or even consult in 
their research. Remember that in many high throughput data collections 90+% of 
proteins/genes show no significant change. It may be that at present the most useful result of 
the high-throughput studies would be to identify which proteins in which contexts the wet 
biologists should investigate in detail. Our recent experience is that while initial high coverage of 
large numbers of proteins is necessary for identifying “potentially interesting” proteins, then 
priority should be given to methods that provide deep coverage of abundance, transcriptional/ 
translational isoforms, subcellular location, PTMs, binding partners, etc. for about 500 proteins. 
This seems to be a sufficient number, even for strong cellular perturbations such as cell cycle 
arrest occasioned by blocking DNA replication or by oxidative stress. This tends to give lots of 
fragmented functional networks that are ripe for further wet biology characterization by the many 
specialists in particular functional subsystems, although it is hard to get journals to let one 
present them all in a single publication. A lot more thought and effort should go into how to 
integrate and coordinate the typically incomplete, fragmented large scale results with smaller 
scale studies. Maybe adapting recent efforts in systems biology markup languages to include 
things like dynamic spatial location would provide a useful interface between the two 
communities.  This would facilitate contextual recording of “predicted” fragment networks in 
forms that wet biologists could use, allow recording of small scale results in an efficient form, 
record “confirmed” fragments that would be useful components in trying to construct more 
informative global networks, could be adopted by journals as a publication standard to facilitate 
presentation and interchange, and could be collected in open access libraries. 
      
     How do you envision proteomics taking a more holistic approach in future? 
 Proteomics is already both holistic and fine grained. For example, we can already monitor 
abundance for most of the roughly 10,000 proteins that are used in any given cell type. Because 
transcription, translation and degradation all contribute to abundance of proteins in cells, this 
gives more complete information on the state of cells than genomics or transcriptomics 
measurements. We can already monitor at a global proteome-scale crucial processes such as 
PTMs involved in signalling systems that are invisible to genomics methods. We are making 
progress towards proteome-scale measurement of the dynamic spatial distribution of proteins. I 
think we are currently on a path similar to what has happened with genomics and evolution. 
Massive amounts of new data are replacing the original concept of the genome as a read-only 
memory with concepts of the genome as a read-write memory in which proteomic, and also 
metabolic, inputs re-shape the genome. Epigenetics is the short term reshaping of the genome 
and evolution the longer term reshaping. In some ways we might even regard the genome as a 
kind of flash memory that a complex adaptive system interacting with its environment finds 
useful in maintaining itself, but is re-written when maintenance makes that useful.  
 Sometimes the devil is in the details and proteomics is very good at focussing on detailed 
changes for a few target proteins. Seeing all the details during global measurements is still 
beyond our current technology. We will get better at including more of the details in global 
measurements, but I suspect that in many cases it will be more productive to flesh out the 
global picture with targeted in-depth studies that focus on subsystems. From the standpoint of 
practical applications in therapy and diagnostics, I think it remains to be seen whether global 
features or local, detailed features are the most useful. Probably the most efficacious level for 
both therapy and diagnostics is an intermediate regime of functional subsystems that smooth 
out differences between billions of individuals. At the moment we have a kind of paradox that 
we can increasingly measure individual genomic differences in excruciating detail, but we often 
don’t know enough about the intermediate regime of cellular function to make those differences 
useful in the development or application of therapy and diagnostics. So far proteomics seems to 
be the technology that best monitors concurrently many different aspects of the intermediate 
regime and it therefore has a crucial role to play in developing both therapy and diagnostics.  
     
      What is your proudest achievement in your career so far? 
Difficult question. I think that I am most satisfied to have made a useful contribution towards 
new concepts during each epoch of my career. I had the good fortune to do my PhD and 
continue to work at Max Planck Institute in Munich in contact with scientists of the calibre of 
Perutz, Goodman, Mayr, Edman and Braunitzer. Protein structural biology was still in its infancy 
and I was given the job of determining the sequence of avian hemoglobins so we could think 
about why some birds can fly so high or don’t suffer from rapid changes in altitude (oxygen 
pressure). That was an early beginning of fields like computational structural biology that 
eventually led to further Nobel prizes. But I left Munich and in Canberra I went in a different 
direction to look at transport of insoluble molecules like retinoic acid. We defined a new family of 
related protein structures called lipocalins1 that made it into the textbooks as important 
physiological transporters of lipidic molecules. During the next stages I established new 
methods for extracting G-protein coupled receptors from membranes and determined structures 
and post-translation modifications (PTMs) for several2. This got me interested in cellular 
signalling and we published some of the first papers on intertwined dynamic changes in cellular 
phosphorylation networks and on multiple, different PTM patterns for the same protein that 
represent different functional states. One aspect was competitive modification of 
phosphorylation or acetylation in RhoGdi Protein PTMs in signalling systems has since become 
an enormous field that has feverish activity and in which we still participate. I moved on to 
spatial aspects of cellular function and we published work on nucleo-cytplasmic trafficking of 
proteins, including things like glycolytic enzymes in the nucleus, well before this became wildly 
popular in areas like the molecular-level connections of hypoxia to cancer3. This brought me to 
our present attempts to better define the role of dynamic spatial distribution of proteins in 
cellular function. 
      What do you predict for the interplay between proteomics and molecular diagnostics in 
future? 
 I think there are three crucial components to molecular diagnostics: sensitivity, specificity and 
what I will call uniqueness. We have only been peripherally involved in molecular diagnostics, 
mostly when we worked a number of years ago on extending the sensitivity of antibody 
detection of proteins to low femtomole or even attomole amounts with multi-photon detection 
methods. At the time we satisfied ourselves that proteomics methods have sufficient sensitivity 
for effective medical molecular diagnostics and recent developments in areas like quantum dots 
certainly confirm this. Specificity for large numbers of antibodies and very large variations in the 
cellular abundance of different proteins are crucial questions in efforts to use antibody-based 
proteomics for global monitoring of cellular function, especially for analysis of the quantitative 
aspects of highly coupled networks. These are difficult problems that are mostly skirted in 
diagnostics applications since highly specific antibody detection of panels of limited numbers of 
proteins can be optimized. I think the real question about the future of proteomics in molecular 
diagnostics has to do with uniqueness. If potentially critical aspects of cellular function such as 
PTMs and their coupling to dynamic spatial organization of cells are largely invisible to the very 
efficient detection methodology of genomic methods, can proteomics monitoring of limited 
numbers of proteins provide detection of features that are unique to specific diseases and not 
otherwise detectable? It is already pretty evident that single proteins/genes are often only 
moderately helpful and that panels are needed. At present this seems to be an open question, 
but I think there are good prospects for proteomics. I would predict that the key once again lies 
in the intermediate regime of functional networks mentioned above. We need diagnostics that 
efficiently monitor the functioning of the intermediate subsystems, maybe even independent of 
the details of genetic variation, infectious agent or changes accumulated over a lifetime. This is 
potentially where a critical symbiotic coupling between diagnostics and therapy really comes 
into play and where proteomics could be crucial. 
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